FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
2 Beaten-Down Stocks to Avoid Right Now
There might be plenty more downside for these biotechs.
Sarepta Shares Jump After FDA Approves Updated Elevidys Label - Sarepta Therapeutics ( NASDAQ:SRPT )
Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) stock jumped on Friday after the FDA issued a new boxed warning for Elevidys. The updated approval follows recent reports of fatal liver injury in non-ambulatory pediatric patients who received the gene therapy. SRPT stock is moving.
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Boise Cascade ( NYSE:BCC ) , CervoMed ( NASDAQ:CRVO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure
Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.
Gold Falls Over 1%; Uber Shares Decline After Q3 Results - Evoke Pharma ( NASDAQ:EVOK ) , Denny's ( NASDAQ:DENN )
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 350 points on Tuesday. The Dow traded down 0.60% to 47,053.04 while the NASDAQ dipped 1.65% to 23,441.48. The S&P 500 also fell, dropping, 1.05% to 6,780.03. Financial shares jumped by 0.4% on Tuesday.
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance - Sarepta Therapeutics ( NASDAQ:SRPT )
Sarepta Therapeutics Inc. ( NASDAQ:SRPT ) shared topline data from the ESSENCE Phase 3 trial of Amondys 45 ( casimersen ) and Vyondys 53 ( golodirsen ) compared with placebo in 225 patients aged 6-13 years with Duchenne muscular dystrophy amenable to exon 45 or 53 skipping.
Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It - Sarepta Therapeutics ( NASDAQ:SRPT )
Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" Martin Shkreli said he still likes the stock. SRPT stock is crashing. See the real-time price ...
Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Atlas Energy Solutions ( NYSE:AESI ) , Archer-Daniels-Midland ( NYSE:ADM )
U.S. stock futures were lower this morning, with the Dow futures falling more than 300 points on Tuesday. Shares of Insperity Inc ( NYSE:NSP ) fell sharply in pre-market trading after the company reported worse-than-expected third-quarter financial results and cut its FY25 adjusted EPS and GAAP ...
Why Upwork Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket - Atlas Energy Solutions ( NYSE:AESI ) , Ardelyx ( NASDAQ:ARDX )
Shares of Upwork Inc ( NASDAQ:UPWK ) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance above estimates. Also, the company raised its FY25 guidance above estimates.
Sarepta Therapeutics ( SRPT ) Reports Q3 Loss, Beats Revenue Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -1,400.00% and +13.26%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics Stock Is Tumbling After The Close: Here's Why - Sarepta Therapeutics ( NASDAQ:SRPT )
Sarepta Therapeutics Inc ( NASDAQ:SRPT ) shares are plunging in extended trading Monday after the company reported third-quarter results and provided an update on its ESSENCE study. What To Know: Sarepta reported third-quarter revenue of $399.36 million, beating analyst estimates of $338.71 ...
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More - Palantir Technologies ( NASDAQ:PLTR )
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. Here's a look at the names most likely to be on individual investors' radars. CIFR stock is soaring. Watch the real-time price action here.
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
Highly experienced biopharma financial officer joins leadership team ...
Beam Therapeutics Inc. ( BEAM ) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tradr's 9 2X ETFs With First-Of-Its-Kind Gold And AI Exposure - Bullish ( NYSE:BLSH ) , DoorDash ( NASDAQ:DASH )
Tradr ETFs has introduced nine new single-stock leveraged ETFs designed to provide twice the daily performance of their underlying stocks. Seven of these ETFs are first-to-market strategies.
What's Going On Sarepta Stock On Wednesday? - Sarepta Therapeutics ( NASDAQ:SRPT )
Sarepta Therapeutics Inc. ( NASDAQ:SRPT ) stock is trading higher on Wednesday, with apparently no news to justify the movement. This week, Sarepta will present data from its gene therapy, delandistrogene moxeparvovec, for Duchenne muscular dystrophy ( DMD ) .
Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday - Angel Studios ( NYSE:ANGX )
U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday. Shares of Taysha Gene Therapies Inc ( NASDAQ:TSHA ) rose sharply during Thursday's session after the FDA granted the company Breakthrough Therapy designation to TSHA-102 for the treatment of Rett syndrome.
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - FactSet Research Systems ( NYSE:FDS ) , Brinker International ( NYSE:EAT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Barclays analyst Eddie Kim upgraded Helmerich & Payne, Inc.
2 Beaten-Down Stocks to Avoid Right Now
These once high-flying stocks no longer seem to have promising prospects.
Top 20 Most-Searched Stock Tickers on Pro in August - Apple ( NASDAQ:AAPL )
A look at the 20 most-searched tickers on Benzinga Pro for the month of August. The list includes two companies buying up Ethereum for their balance sheets. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day
SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN DIEGO, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. SRPT securities between June 22, 2023 and June 24, 2025.
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT of a class action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ( or ...
Muscular Dystrophy Association Launches #MDAstrong Campaign in September During Historic 75th Anniversary, Kicking Off on Labor Day Weekend
New York, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- This September, the Muscular Dystrophy Association ( MDA ) is launching its milestone #MDAstrong campaign during a historic moment for the organization: its 75th anniversary.
SRPT FINAL DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline in Securities Class Action - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 23, 2025 ( GLOBE NEWSWIRE ) -- A securities class-action lawsuit is underway against Sarepta Therapeutics SRPT, triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ...
MONDAY INVESTOR DEADLINE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT
MONDAY INVESTOR DEADLINE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit ...
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options
SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 23, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
SRPT 3-DAY DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- A securities class-action lawsuit is underway against Sarepta Therapeutics SRPT, triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ...
SRPT FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. SRPT between June 22, 2023 and June 24, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ( or ...
What's Going On With Sarepta Shares Thursday? - Sarepta Therapeutics ( NASDAQ:SRPT )
Sarepta swaps $700 million of 2027 notes for $602 million of new 2030 notes, stock, and cash. The new notes convert at $60 per share, a 191.5% premium to the last close of $20.58. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
SRPT DEADLINE NOTICE: Sarepta Therapeutics, Inc. Investors are Notified of the August 25 Class Action Deadline -- Contact BFA Law if You Suffered Losses ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN DIEGO, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. SRPT securities between June 22, 2023 and June 24, 2025, inclusive ( the "Class Period" ) , have until Monday, August 25, 2025 to seek appointment ...
SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- A securities class-action lawsuit is underway against Sarepta Therapeutics SRPT, triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ...
SRPT Investors Have the Opportunity to Lead the Sarepta Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Sarepta Therapeutics ( NASDAQ:SRPT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
SRPT SECURITIES: Sarepta Therapeutics, Inc. Shareholders that Lost Money may have been Affected by Fraud -- Contact BFA Law before the Class Action Deadline ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Robbins LLP Reminds Sarepta Therapeutics, Inc. Stockholders of the Pending Lead Plaintiff Deadline in the Securities Class Action Against SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN DIEGO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. SRPT securities between June 22, 2023 and June 24, 2025.
Contact The Gross Law Firm by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. ( SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. SRPT. Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...
Sarepta Therapeutics ( SRPT ) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- The pending securities class action was triggered after news of safety problems with Sarepta's SRPT ELEVIDYS, a medication intended for the treatment of Duchenne muscular dystrophy.
SRPT INVESTOR NOTICE: Robbins Geller Ruman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN DIEGO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc.
SRPT LOSS ALERT: Sarepta Therapeutics, Inc. Investors with Losses are Reminded of the August 25 Class Action Deadline - Contact BFA Law ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
SRPT IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 16, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. SRPT between June 22, 2023 and June 24, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - Sarepta Therapeutics ( NASDAQ:SRPT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 16, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT in the United States District Court for the ...
SRPT FRAUD REMINDER: Sarepta Therapeutics, Inc. Stock Drop Triggers Securities Fraud Class Action - Contact BFA Law before Imminent August 25 Deadline ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 15, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
How Do Investors Really Feel About Sarepta Therapeutics? - Sarepta Therapeutics ( NASDAQ:SRPT )
Sarepta Therapeutics's SRPT short percent of float has risen 41.95% since its last report. The company recently reported that it has 20.95 million shares sold short, which is 25.14% of all regular shares that are available for trading.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - Sarepta Therapeutics ( NASDAQ:SRPT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options
